Literature DB >> 30584711

[IFN-γ induces overexpression of PD-L1 and epithelialmesenchymal transformation of breast cancer cells through activating ERK/Jak2-STAT signaling pathways].

Yurong Yan1, Chenchen Zhao1, Rui Yang1, Ting Zhou1, Na Xu1.   

Abstract

To investigate the effect of INF-γ on the expression of programmed death ligand 1 (PD-L1), epithelial-mesenchymal transition (EMT) and the potential mechanism in breast cancer cell line MDA-MB-231, the cells were treated with different concentrations of INF-γ. The expressions of proteins, including PD-L1, cell-migration-related proteins (E-cadherin, N-cadherin and vimentin), ERK, p-ERK, Jak2, and p-Jak2 were detected by Western blotting analysis and immunofluorescent staining assay. Cell migration was studied through cell wound healing assay and transwell assay. IFN-γ could up-regulate the expressions of PD-L1 in MDA-MB-231 cells. The cell migration rate was significantly increased after adding IFN-γ. The expression levels of vimentin and N-cadherin were increased whereas the expression of E-cadherin was decreased after adding IFN-γ. The expression levels of ERK, p-ERK, Jak2 and p-Jak2 were significantly increased and this phenomenon was inhibited when adding ERK inhibitor U0126 or Jak2 inhibitor AG490. These results demonstrate that IFN-γ could up-regulate the expression of PD-L1, promote cell migration and transmission, and facilitate epithelial-mesenchymal transformation of breast cancer cells and this process may be related with ERK and Jak2-STAT signaling pathways.

Entities:  

Keywords:  ERK; IFN-γ; Jak2; PD-L1; breast cancer; epithelial-mesenchymal transition

Mesh:

Substances:

Year:  2018        PMID: 30584711     DOI: 10.13345/j.cjb.180070

Source DB:  PubMed          Journal:  Sheng Wu Gong Cheng Xue Bao        ISSN: 1000-3061


  1 in total

1.  Degradation of BRD4 - a promising treatment approach not only for hematologic but also for solid cancer.

Authors:  Karin Bauer; Anna S Berghoff; Matthias Preusser; Gerwin Heller; Christoph C Zielinski; Peter Valent; Thomas W Grunt
Journal:  Am J Cancer Res       Date:  2021-02-01       Impact factor: 6.166

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.